Thailand Cannabis Policy: Medical Framework, Enforcement & Legal Status

Executive Summary

Thailand's cannabis policy has undergone dramatic reversals since 2022, transforming from Southeast Asia's most liberal regime to a tightly controlled medical-only framework. In June 2022, Thailand became the first Asian nation to decriminalize cannabis, removing it from its narcotics list and sparking a commercial boom with thousands of dispensaries opening nationwide. However, mounting public health concerns and political pressure led to a swift policy reversal in 2024, when the Thai parliament re-criminalized recreational use while preserving a medical cannabis pathway. As of June 2026, authorities have conducted more than 1,200 nationwide inspections to enforce the medical-only framework, targeting unlicensed dispensaries and recreational sales.

The policy whiplash has created regulatory uncertainty for patients, businesses, and international observers. Thailand's medical cannabis program now requires strict licensing from the Food and Drug Administration, limits THC content in consumer products, and restricts cultivation to registered entities. The enforcement campaign reflects the government's determination to close loopholes that allowed de facto recreational sales under the guise of medical use. For stakeholders across the global cannabis industry, Thailand's experience serves as a cautionary tale about the fragility of liberalization without comprehensive regulatory frameworks and the political volatility surrounding cannabis reform in conservative societies.

Why This Matters

Thailand's cannabis policy directly affects 70 million citizens, thousands of businesses, regional medical cannabis patients, and international investors who bet on Southeast Asian market expansion. The 2022 decriminalization triggered investment of an estimated $1.2 billion into Thai cannabis ventures, according to industry analysts, with projections that the market could reach $2 billion annually by 2025. The subsequent re-criminalization in 2024 stranded capital, forced business closures, and created legal jeopardy for operators who had invested based on the liberalized regime.

For patients, the stakes are equally high. Thailand's medical cannabis program provides legal access to treatments for chronic pain, epilepsy, chemotherapy side effects, and other conditions where conventional therapies have failed. The June 2026 enforcement sweep raises concerns about access continuity, as inspections have shuttered some dispensaries that served legitimate medical users alongside recreational customers. Patient advocacy groups have reported supply disruptions in provinces outside Bangkok, where the medical infrastructure remains underdeveloped.

Regionally, Thailand's policy serves as a bellwether for cannabis reform across Asia. Countries including Malaysia, South Korea, and the Philippines have watched Thailand's experiment closely as they consider their own medical cannabis frameworks. The reversal has emboldened conservative factions in neighboring countries who argue that liberalization inevitably leads to public health crises and social disorder. Conversely, reform advocates point to Thailand's lack of regulatory preparation—not cannabis itself—as the root cause of problems.

For multinational cannabis companies, Thailand represented a potential gateway to Asian markets with a combined population exceeding 4.5 billion people. Canadian licensed producers, U.S. multi-state operators, and European pharmaceutical firms had established partnerships with Thai cultivators and distributors. The policy reversal has forced a reassessment of regional expansion strategies and highlighted the risks of operating in jurisdictions without constitutional protections for cannabis commerce.

Background and History: From Prohibition to Liberalization and Back

Thailand's cannabis journey spans nearly a century, from traditional medicine use to strict prohibition under international pressure, followed by a brief liberalization and subsequent re-criminalization.

Traditional Use and Early Prohibition (Pre-1979)

Cannabis has been used in traditional Thai medicine for centuries, particularly in rural communities where it treated pain, digestive ailments, and fatigue. Thai traditional medicine practitioners incorporated cannabis into herbal remedies, often combined with other botanicals. The plant grew wild in many regions and faced no legal restrictions until the 20th century.

Thailand's first cannabis prohibition came in 1934 under the Marijuana Act, which classified cannabis as a controlled substance. However, enforcement remained lax, and traditional use continued in rural areas. The modern prohibition regime solidified in 1979 when Thailand enacted the Narcotics Act B.E. 2522, which classified cannabis as a Category 5 narcotic—the strictest classification, grouping it with heroin and methamphetamine. This legislative change came under pressure from the United States and international drug control treaties, particularly the 1961 Single Convention on Narcotic Drugs.

Medical Cannabis Legalization (2018-2019)

Thailand's first step toward reform came on December 25, 2018, when the military-backed National Legislative Assembly amended the Narcotics Act to allow medical cannabis use. The amendment, which took effect on February 18, 2019, permitted licensed medical facilities to prescribe cannabis for specific conditions and allowed registered researchers to cultivate the plant for medical and scientific purposes.

The 2018 reform made Thailand the first Southeast Asian nation to legalize medical cannabis. Public Health Minister Piyasakol Sakolsatayadorn championed the policy as a way to provide treatment options for patients while creating economic opportunities for Thai farmers. The government emphasized that cannabis had been part of Thai traditional medicine for generations and that legalization would reclaim this heritage.

Initial implementation moved slowly. The Food and Drug Administration established a registration system for medical cannabis products, but only government hospitals and a handful of licensed clinics could dispense them. Patients faced bureaucratic hurdles to access treatment, and the supply remained limited to government-controlled cultivation facilities.

Full Decriminalization (June 2022)

The transformative moment came on June 9, 2022, when Thailand's Ministry of Public Health removed cannabis and hemp from the Category 5 narcotics list, effectively decriminalizing possession and cultivation. The policy change, championed by then-Public Health Minister Anutin Charnvirakul, leader of the Bhumjaithai Party, made Thailand the first Asian country to decriminalize cannabis.

The decriminalization allowed individuals to grow cannabis plants at home after registering with authorities via the government's Plook Ganja mobile application. Commercial cultivation, processing, and sales became legal for entities registered with the Food and Drug Administration. The government framed the policy as an economic development initiative that would benefit farmers and position Thailand as a regional leader in cannabis medicine and wellness products.

The regulatory framework, however, contained critical gaps. While the law prohibited recreational use and marketing cannabis for non-medical purposes, it lacked clear definitions of medical versus recreational use and provided minimal enforcement mechanisms. The government issued guidelines limiting THC content in food and beverages to 0.2 percent, but enforcement proved inconsistent.

The Commercial Boom (2022-2024)

Decriminalization triggered explosive commercial growth. Within six months, more than 6,000 cannabis dispensaries opened across Thailand, concentrated in Bangkok, Phuket, Chiang Mai, and other tourist destinations. Many operated as "cannabis cafes" that sold flowers, pre-rolls, and infused products in a retail environment indistinguishable from recreational dispensaries in U.S. states like California or Colorado.

The industry attracted domestic and international investment. Thai conglomerates including Charoen Pokphand Group and Siam Cement Group announced cannabis ventures. Canadian companies including Canopy Growth and Aurora Cannabis established partnerships with Thai cultivators. By late 2023, Thailand had issued more than 1.2 million household cultivation licenses and registered over 8,000 commercial cannabis entities, according to the Food and Drug Administration.

Tourism operators marketed Thailand as a cannabis destination, particularly targeting visitors from countries with strict prohibition. Cannabis-themed hotels, cooking classes, and wellness retreats proliferated. Industry advocates projected that cannabis could generate $1.8 billion in annual economic activity and create 45,000 jobs by 2025.

Public Health Concerns and Political Backlash (2023-2024)

The rapid commercialization generated public health and social concerns that fueled political opposition. Emergency room visits related to cannabis intoxication increased, particularly among adolescents who accessed products marketed as "herbal relaxation" aids. The Public Health Ministry reported a 150 percent increase in cannabis-related emergency department visits between June 2022 and June 2023, though the absolute numbers remained small compared to alcohol-related incidents.

Parents' groups and conservative politicians criticized the policy as enabling youth drug use. The Thai Medical Association raised concerns about products with unverified THC content and lack of quality control. Buddhist religious leaders objected to cannabis use as contrary to precepts against intoxicants. Opposition parties, particularly the Democrat Party and Palang Pracharath Party, made re-criminalization a campaign issue in the 2023 general election.

The political landscape shifted after the May 2023 election, which saw the progressive Move Forward Party and Pheu Thai Party gain parliamentary strength. While these parties supported medical cannabis, they opposed the unregulated commercial market that had emerged. The Bhumjaithai Party, which had championed decriminalization, lost political influence in coalition negotiations.

Re-Criminalization (January 2024)

On January 8, 2024, the Thai parliament passed the Cannabis and Hemp Act B.E. 2567, which re-criminalized recreational cannabis use while preserving a medical pathway. The law, which took effect on March 1, 2024, reclassified cannabis as a controlled substance requiring medical authorization for legal possession and use.

The 2024 law established several key provisions. It limited legal cannabis use to medical purposes under prescription from licensed physicians. It required all cannabis businesses to obtain medical cannabis licenses from the Food and Drug Administration, with strict criteria including pharmaceutical-grade facilities and qualified medical personnel. It set maximum THC limits of 0.2 percent for hemp-derived consumer products and required medical cannabis products to be dispensed only through licensed pharmacies or medical facilities.

The law imposed criminal penalties for recreational use, including fines up to 60,000 baht (approximately $1,700) and imprisonment up to one year for possession without medical authorization. It established a six-month transition period during which existing businesses could apply for medical licenses or cease operations.

The re-criminalization sparked protests from business owners who had invested based on the 2022 decriminalization. Industry groups filed legal challenges arguing that the retroactive application violated property rights and constitutional protections. However, Thailand's Constitutional Court declined to issue an injunction, allowing the law to take effect as scheduled.

Enforcement Intensification (2024-2026)

Following the March 2024 effective date, Thai authorities launched a phased enforcement campaign. The Food and Drug Administration initially focused on education and voluntary compliance, conducting workshops for businesses on medical licensing requirements. However, as the transition period expired in September 2024, enforcement became more aggressive.

Police and FDA inspectors conducted joint operations targeting unlicensed dispensaries, particularly in tourist areas where recreational sales continued despite the legal change. Between September 2024 and December 2025, authorities shut down more than 3,800 cannabis businesses for operating without medical licenses, according to the Public Health Ministry. Many operators had been unable to meet the stringent requirements for medical licensing, which included employing licensed pharmacists, maintaining pharmaceutical-grade storage, and implementing physician oversight.

The June 2026 enforcement sweep, which involved more than 1,200 inspections nationwide, represented the most intensive crackdown to date. Authorities targeted businesses that had continued operating in a legal gray area by claiming to serve medical patients but lacking proper documentation and physician oversight. The operation resulted in 287 business closures and 156 arrests for unlicensed cannabis sales, according to preliminary reports from the Royal Thai Police.

Key Players

Ministry of Public Health and Food and Drug Administration

The Ministry of Public Health serves as the primary regulatory authority for cannabis policy in Thailand. The ministry's Food and Drug Administration implements licensing, quality control, and enforcement programs. Under the current medical-only framework, the FDA issues licenses to cultivators, processors, and dispensaries that meet pharmaceutical standards. The agency conducts inspections, tests products for THC content and contaminants, and coordinates with police on enforcement actions against unlicensed operators.

The ministry has faced criticism from both sides of the cannabis debate. Patient advocates argue that licensing requirements are too stringent and limit access, particularly in rural provinces. Industry groups contend that the FDA lacks sufficient personnel and resources to process license applications efficiently, creating bottlenecks. Conversely, conservative groups argue that enforcement remains too lax and that the FDA has failed to prevent recreational sales disguised as medical use.

Bhumjaithai Party

The Bhumjaithai Party, led by Anutin Charnvirakul, championed the 2022 decriminalization and continues to advocate for cannabis liberalization. The party, which draws support from rural agricultural constituencies, framed cannabis as an economic opportunity for farmers and positioned Thailand as a potential global leader in cannabis medicine. Following the 2024 re-criminalization, Bhumjaithai has called for easing medical licensing requirements and allowing home cultivation for personal medical use.

The party's political influence has waned since the 2023 election, limiting its ability to shape policy. However, it retains a coalition role in the current government and continues to push for reforms that would expand the medical cannabis program while maintaining controls on recreational use.

Thai Cannabis Corporation and Industry Associations

The Thai Cannabis Corporation, an industry association representing licensed medical cannabis businesses, has lobbied for regulatory clarity and streamlined licensing processes. The organization represents approximately 400 licensed cultivators, processors, and dispensaries that have successfully transitioned to the medical framework. It has advocated for expanding the list of qualifying medical conditions, allowing telemedicine consultations for cannabis prescriptions, and reducing licensing fees that many operators find prohibitive.

Other industry groups, including the Highland Research and Development Institute and the Thai Traditional and Alternative Medicine Association, have focused on preserving cannabis access for traditional medicine practitioners and rural communities that have historically used the plant.

Patient Advocacy Organizations

Organizations including the Thai Medical Cannabis Association and the Cannabis Patient Network have advocated for patient access and opposed overly restrictive regulations. These groups have documented cases of patients who lost access to cannabis medicine following the 2024 re-criminalization, particularly in provinces where no licensed medical cannabis dispensaries operate. They have called for expanding the network of licensed providers, allowing nurse practitioners to prescribe cannabis, and establishing a compassionate use program for patients with serious illnesses.

Opposition and Conservative Groups

The Democrat Party and conservative civil society organizations have opposed cannabis liberalization on public health and moral grounds. The Foundation for a Drug-Free Thailand, a prominent anti-drug advocacy group, has called for complete re-prohibition and criticized the medical cannabis program as a loophole for recreational use. These groups have cited increases in youth cannabis use and emergency room visits as evidence that any legal cannabis framework poses unacceptable risks.

Legal and Regulatory Framework

Thailand's current cannabis legal framework rests on the Cannabis and Hemp Act B.E. 2567 (2024), which superseded the 2022 decriminalization and re-established cannabis as a controlled substance with a medical exception.

Statutory Basis

The Cannabis and Hemp Act B.E. 2567 defines cannabis as any part of the Cannabis sativa L. plant, including flowers, leaves, seeds, and extracts. The law distinguishes between hemp, defined as cannabis plants containing no more than 0.2 percent THC by dry weight, and medical cannabis, which may contain higher THC levels but requires medical authorization.

The act establishes three categories of legal cannabis activity. First, hemp cultivation and processing for industrial purposes, including fiber, seeds, and low-THC extracts, requires registration with the Department of Agriculture but does not require medical licensing. Second, medical cannabis cultivation, processing, and distribution requires licenses from the Food and Drug Administration and compliance with Good Manufacturing Practice standards. Third, medical cannabis possession and use by patients requires a prescription from a licensed physician and registration with the FDA.

The law prohibits recreational use, defined as possession or consumption without medical authorization. Violations carry penalties including fines up to 60,000 baht and imprisonment up to one year for first offenses. Repeat offenses and commercial-scale unlicensed sales carry enhanced penalties up to five years imprisonment.

Licensing Requirements

The Food and Drug Administration has established detailed licensing criteria for medical cannabis businesses. Cultivation licenses require applicants to demonstrate secure growing facilities, quality control protocols, and tracking systems that document plants from seed to sale. Applicants must employ at least one person with a degree in agriculture, pharmacy, or a related field and must submit to unannounced FDA inspections.

Processing licenses require pharmaceutical-grade facilities that meet Good Manufacturing Practice standards. Applicants must employ a licensed pharmacist as quality control manager and must test all products for THC content, CBD content, pesticides, heavy metals, and microbial contamination. Products must be packaged in child-resistant containers with labels listing all cannabinoid content and health warnings.

Dispensary licenses require applicants to employ a licensed pharmacist who must be present during all business hours. Dispensaries must maintain patient records documenting prescriptions and purchase quantities. They must store cannabis products in locked areas with security systems and must report inventory to the FDA monthly. Dispensaries cannot advertise to the general public and cannot be located within 300 meters of schools, temples, or government buildings.

Prescription and Patient Access

Patients seeking medical cannabis must obtain a prescription from a licensed physician. The law does not specify qualifying conditions, leaving prescription decisions to physician discretion. However, FDA guidelines indicate that cannabis should be considered only after conventional therapies have failed and should be prescribed for conditions including chronic pain, epilepsy, chemotherapy side effects, multiple sclerosis, and glaucoma.

Physicians must register with the Medical Council of Thailand to prescribe cannabis and must complete a training program on cannabis pharmacology and patient monitoring. Prescriptions are valid for 30 days and specify the product type, THC and CBD content, and maximum daily dose. Patients must present prescriptions at licensed dispensaries and can possess up to a 30-day supply.

International Treaty Obligations

Thailand's cannabis policy operates within the constraints of international drug control treaties, particularly the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. These treaties, to which Thailand is a party, require signatories to limit cannabis to medical and scientific purposes and to prevent diversion to recreational use.

The 2022 decriminalization created tension with treaty obligations, as the lack of medical controls arguably violated the requirement to limit cannabis to medical purposes. The 2024 re-criminalization brought Thailand back into clearer compliance by establishing medical-only access and prohibiting recreational use. However, some international drug control experts have questioned whether Thailand's medical program, which allows physician discretion rather than limiting cannabis to specific conditions, meets the treaty requirement for strict medical limitation.

Market and Business Implications

The policy reversal from 2022 decriminalization to 2024 re-criminalization has devastated Thailand's cannabis industry, with an estimated 70 percent of businesses closing and investment capital fleeing the sector.

Business Closures and Stranded Capital

Of the approximately 8,000 cannabis businesses that operated during the 2022-2024 decriminalization period, fewer than 2,000 have successfully obtained medical licenses and remain operational as of June 2026, according to Food and Drug Administration data. The stringent licensing requirements—particularly the need for pharmaceutical-grade facilities and licensed pharmacists—proved insurmountable for most operators, especially small businesses and individual entrepreneurs.

Industry analysts estimate that investors lost between $800 million and $1.2 billion in stranded capital, including investments in cultivation facilities, retail buildouts, inventory, and branding. Many businesses had signed multi-year leases for retail space in prime locations, creating ongoing financial obligations even after forced closures. Some operators have attempted to pivot to hemp-derived products with THC content below 0.2 percent, but this market segment has proven far less lucrative than the medical cannabis sector.

Surviving Medical Cannabis Operators

The licensed medical cannabis businesses that survived the transition tend to be larger, well-capitalized entities with pharmaceutical industry experience. Several Thai pharmaceutical companies, including Greater Pharma and Siam Pharmaceutical, have entered the medical cannabis market with vertically integrated operations spanning cultivation, processing, and dispensing. These companies have leveraged existing Good Manufacturing Practice facilities and regulatory expertise to meet licensing requirements.

International partnerships have largely dissolved. Canadian licensed producers including Aurora Cannabis and Canopy Growth have exited their Thai joint ventures, citing regulatory uncertainty and reduced market potential. European pharmaceutical companies have maintained a presence but have scaled back investment pending further policy clarity.

Licensed medical cannabis dispensaries report average monthly revenues of 800,000 to 1.2 million baht ($22,000 to $34,000), significantly lower than the 2-4 million baht monthly revenues that recreational-oriented dispensaries generated during the decriminalization period. The patient base remains limited, with an estimated 150,000 registered medical cannabis patients nationwide as of June 2026, compared to industry projections of 2-3 million potential patients.

Wholesale Pricing and Supply Chain

Wholesale cannabis flower prices have collapsed from peaks of 800-1,200 baht per kilogram ($22-$34) during the 2022-2024 boom to current levels of 200-400 baht per kilogram ($6-$11). The price decline reflects oversupply, as many cultivators continue growing cannabis under hemp licenses despite limited demand from the reduced number of legal medical dispensaries.

The supply chain has consolidated around a small number of licensed processors who purchase flower from cultivators, extract cannabinoids, and formulate medical products including oils, capsules, and topicals. These processors report operating at 30-40 percent of capacity due to limited demand from the medical market. Some have begun exporting hemp-derived CBD extracts to international markets, particularly in Europe and North America, as a way to utilize excess capacity.

Employment Impact

The cannabis industry employed an estimated 35,000-40,000 people at its peak in late 2023, including budtenders, cultivators, processors, and support staff. Industry observers estimate that employment has fallen to approximately 8,000-10,000 as of June 2026, concentrated in licensed medical operations. Many former cannabis workers have returned to conventional agriculture or service industry jobs.

Tourism Sector Effects

Cannabis tourism, which had emerged as a significant draw for international visitors during the decriminalization period, has largely evaporated. Hotels and tour operators that had developed cannabis-themed offerings have discontinued these programs. Tourism industry representatives estimate that cannabis-related tourism generated $200-$300 million in annual economic activity during 2023, revenue that has now been lost.

What Experts Say

Public health officials, legal scholars, and industry analysts have offered divergent assessments of Thailand's cannabis policy trajectory and its implications for patients, businesses, and regional reform efforts.

Dr. Surachoke Tangwiwat, Deputy Director-General of the Department of Medical Services, has defended the medical-only framework as necessary to protect public health while preserving patient access. According to statements to Thai media, Surachoke emphasized that the 2022 decriminalization created a public health crisis with inadequate controls on product quality, THC content, and youth access. He characterized the current medical framework as a balanced approach that allows physicians to prescribe cannabis for legitimate medical needs while preventing recreational use and commercial exploitation.

Patient advocates have challenged this characterization. Taopiphop Limjittrakorn, coordinator of the Cannabis Patient Network, has stated that the stringent licensing requirements have reduced access for patients who previously obtained cannabis medicine through dispensaries that operated during decriminalization. According to Taopiphop, many patients in rural provinces now lack access to licensed medical cannabis dispensaries and cannot afford to travel to Bangkok or other major cities for treatment. He has called for expanding the network of licensed providers and allowing traditional medicine practitioners to dispense cannabis under medical supervision.

Legal scholars have questioned the constitutionality of the retroactive application of criminal penalties to conduct that was legal under the 2022 decriminalization. Professor Worachet Pakeerut of Thammasat University's Faculty of Law has argued that the 2024 law's criminalization of possession and use that occurred during the decriminalization period violates principles of legal certainty and non-retroactivity. However, Thailand's Constitutional Court has not accepted cases challenging the law on these grounds.

International drug policy experts have cited Thailand's experience as evidence of the challenges that countries face when liberalizing cannabis policy without comprehensive regulatory frameworks. Dr. Martin Jelsma of the Transnational Institute, a drug policy research organization, has characterized Thailand's policy reversal as predictable given the lack of preparation for commercial regulation. According to Jelsma, successful cannabis legalization requires years of regulatory development, public education, and political consensus-building—elements that were absent in Thailand's rushed 2022 decriminalization.

Business analysts have warned that the policy instability has damaged Thailand's credibility as a destination for cannabis investment. Asa Larsson, managing director of Prohibition Partners Asia, a cannabis market research firm, has stated that international investors view Thailand as a high-risk jurisdiction following the policy reversal. According to Larsson, the experience has made investors more cautious about other Asian markets considering cannabis reform, including Malaysia and the Philippines.

What's Next

Thailand's cannabis policy faces several critical decision points over the next 12-24 months that will determine whether the medical framework expands, contracts, or remains static.

The Food and Drug Administration is scheduled to complete a comprehensive review of the medical cannabis program by December 2026. The review will assess patient access, product quality, diversion to recreational use, and public health impacts. The findings will inform potential regulatory adjustments, including possible expansion of qualifying conditions, easing of licensing requirements, or further restrictions on THC content and product types.

Legislative proposals to amend the Cannabis and Hemp Act B.E. 2567 are expected to be introduced in the 2027 parliamentary session. The Bhumjaithai Party has indicated it will propose amendments to allow home cultivation of up to six plants for personal medical use, similar to models in some U.S. states. Opposition parties are expected to counter with proposals to further restrict the medical program or eliminate it entirely in favor of pharmaceutical-only cannabis products.

The outcome of the 2027 general election, scheduled for May, will significantly influence cannabis policy direction. If the Bhumjaithai Party gains coalition strength, liberalization amendments may advance. If conservative parties gain influence, further restrictions are likely. Current polling suggests a fragmented parliament with no clear majority, indicating that cannabis policy will remain subject to coalition negotiations.

International developments may also influence Thailand's approach. If neighboring countries including Malaysia or the Philippines implement medical cannabis programs, Thailand may face pressure to remain competitive as a regional medical cannabis hub. Conversely, if these countries maintain prohibition, Thailand's conservative factions may cite regional norms as justification for further restrictions.

The June 2026 enforcement campaign is expected to continue through at least the end of 2026, with authorities targeting remaining unlicensed operators and businesses that claim medical status but lack proper physician oversight. Industry observers anticipate that the number of licensed medical cannabis businesses will stabilize at approximately 1,500-2,000 entities, concentrated in Bangkok, Chiang Mai, Phuket, and other major urban centers.

For patients, the critical question is whether the government will expand the network of licensed providers to improve access in underserved provinces. The Public Health Ministry has announced plans to train physicians in cannabis medicine and to establish medical cannabis clinics in provincial hospitals, but implementation timelines remain unclear. Patient advocates continue to push for telemedicine options that would allow patients in remote areas to consult with cannabis-prescribing physicians via video conference.

Further Reading

• Cannabis and Hemp Act B.E. 2567 (2024) - Full text available from the Royal Thai Government Gazette: http://www.ratchakitcha.soc.go.th
• Thailand Food and Drug Administration - Medical Cannabis Licensing Portal: https://cannabis.fda.moph.go.th
• Ministry of Public Health - Cannabis Policy Updates and Statistics: https://www.moph.go.th
• Narcotics Act B.E. 2522 (1979) as amended - Legal framework for controlled substances: http://www.fda.moph.go.th/sites/drug/en/Pages/law.aspx
• 1961 Single Convention on Narcotic Drugs - United Nations Office on Drugs and Crime: https://www.unodc.org/unodc/en/treaties/single-convention.html
• Transnational Institute - Drug Policy Briefing on Thailand Cannabis Reform: https://www.tni.org/en/publication/thailand-cannabis-policy
• Thai Medical Cannabis Association - Patient Resources and Advocacy: https://www.thaimca.org
• Prohibition Partners - Asia Cannabis Market Reports: https://prohibitionpartners.com/reports/

Update — July 1, 2026: Thailand's Cannabis Recriminalization Collapses Retail Market

Thailand's cannabis retail sector has collapsed following the government's January 2025 recriminalization of recreational cannabis, according to Inside Retail Asia. The reversal ended the June 2022 decriminalization that had removed cannabis from the narcotics list and sparked a rapid expansion of dispensaries and cannabis-infused product retailers across Bangkok and tourist destinations.

The recriminalization reinstated criminal penalties for non-medical cannabis possession and sales, forcing thousands of dispensaries to close or pivot to medical-only operations under stricter licensing requirements. Operators reported immediate inventory losses, lease defaults, and supply chain disruptions as the legal framework shifted from permissive retail to controlled medical access within months.

Industry sources said the policy reversal followed public health concerns and political pressure from conservative factions opposing the 2022 liberalization. The abrupt regulatory change left retailers without transition periods or compensation mechanisms, creating legal uncertainty for operators who had invested in storefronts, branding, and product development under the previous framework.

The collapse affects tourism-dependent businesses that had marketed cannabis products to international visitors, as well as domestic operators serving Thai consumers. Remaining medical cannabis programs require physician authorization and restrict product formats, eliminating the edibles, beverages, and wellness products that had driven retail growth during the 2022-2024 boom period.

This matters because Thailand's recriminalization demonstrates regulatory instability risks in emerging cannabis markets where policy lacks legislative permanence. Operators in jurisdictions considering liberalization face similar vulnerabilities when executive or ministerial decisions can reverse market access without grandfathering provisions or investor protections.

Update — July 3, 2026: Japan Increases Scrutiny of Thai Drug Routes Amid Rising Seizures

Japanese authorities intensified monitoring of drug trafficking routes originating from Thailand following a documented increase in narcotics seizures linked to Thai transit points during the first half of 2026. The heightened scrutiny reflects growing concern among Japanese law enforcement that Thailand's 2022 cannabis decriminalization created unintended vulnerabilities in regional drug supply chains, according to statements from Japan's National Police Agency.

While the reported seizures primarily involved methamphetamine and other controlled substances rather than cannabis itself, Japanese officials cited Thailand's loosened regulatory framework as a potential factor complicating enforcement cooperation. The policy shift raised questions about border control protocols and the capacity of Thai authorities to distinguish between legal domestic cannabis commerce and illicit international trafficking operations.

Thailand's Ministry of Public Health responded that existing bilateral agreements with Japan remain in force and that Thai customs enforcement continues to treat cannabis exports as illegal under international treaty obligations. Ministry officials emphasized that domestic decriminalization did not alter Thailand's commitments under the 1961 Single Convention on Narcotic Drugs, which prohibits cross-border cannabis trade outside narrow medical and scientific channels.

The diplomatic friction underscores operational risks for Thai cannabis businesses, as international perception of regulatory gaps could trigger stricter export controls or enhanced inspections affecting legitimate agricultural and pharmaceutical shipments. Industry observers noted that sustained foreign scrutiny may accelerate domestic calls for clearer licensing standards and tighter supply chain tracking to preserve Thailand's trade relationships with enforcement-focused partners like Japan.